ישראל -
עברית -
Ministry of Health
איקלוסיג 15 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 15 mg - ponatinib
ישראל -
עברית -
Ministry of Health
איקלוסיג 30 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 30 mg - ponatinib
ישראל -
עברית -
Ministry of Health
איקלוסיג 30 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 30 mg - ponatinib
ישראל -
עברית -
Ministry of Health
איקלוסיג 45 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 45 mg - ponatinib
ישראל -
עברית -
Ministry of Health
איקלוסיג 45 מג
medison pharma ltd - ponatinib as hydrochloride - טבליות מצופות - ponatinib as hydrochloride 45 mg - ponatinib
ישראל -
עברית -
Ministry of Health
פמאזיר 13.5 מג
medison pharma ltd - pemigatinib - טבליה - pemigatinib 13.5 mg - pemigatinib
ישראל -
עברית -
Ministry of Health
פמאזיר 4.5 מג
medison pharma ltd - pemigatinib - טבליה - pemigatinib 4.5 mg - pemigatinib
ישראל -
עברית -
Ministry of Health
פמאזיר 9 מג
medison pharma ltd - pemigatinib - טבליה - pemigatinib 9 mg - pemigatinib
ישראל -
עברית -
Ministry of Health
קסניקל
tzamal bio-pharma ltd - orlistat - קפסולות - orlistat 120 mg - orlistat - orlistat - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.
ישראל -
עברית -
Ministry of Health
קומפטקט 15 מג 850 מג
tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.